/WUHN

WUHN Stock - Wuhan General Group (China), Inc.

Q: What is the analyst price target for WUHN?

Analyst price target information is not currently available for WUHN.

Q: What is WUHN's market cap?

Market capitalization information is not currently available for WUHN.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for WUHN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-8.03

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020	FY2019
Revenue	$14,176	$33,276	N/A
Gross Profit	$1,375	$17,473	N/A
Gross Margin	9.7%	52.5%	N/A
Operating Income	$-1,684,520	$-120,490	$-179,620
Net Income	$-1,713,443	$409,996	$-210,392
Net Margin	-12086.9%	1232.1%	N/A
EPS	$-0.03	$0.01	$-0.00

Company Overview

Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Pointe-Claire, Canada.

Visit Website

Earnings History & Surprises

WUHN

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-0.10

Q4 2012

EPS Surprise History

Q4 12

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2012	Nov 19, 2012	—	$-0.10	—	—

Frequently Asked Questions about WUHN

What is WUHN's current stock price?

Wuhan General Group (China), Inc. (WUHN) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for WUHN?

No analyst price targets are currently available for this stock.

What sector is Wuhan General Group (China), Inc. in?

Wuhan General Group (China), Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is WUHN's market cap?

Wuhan General Group (China), Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does WUHN pay dividends?

No, Wuhan General Group (China), Inc. does not currently pay a dividend to shareholders.